Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...
healthday6h
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 ...
Medscape3d
Thyroid Cancer Detections Due to More Screenings With GLP-1s
The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...
News Medical on MSN2d
GLP-1RA initiation linked to new thyroid cancer diagnoses
Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...
Medpage Today on MSN7d
More Thyroid Cancers Found After Starting GLP-1s: Researchers Think They Know Why
More thyroid cancers were detected soon after starting a GLP-1 receptor agonist than other diabetes drugs, a secondary ...
HealthDay on MSN3d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...
Healio7d
Increased screening may lead to higher thyroid cancer risk after GLP-1 initiation
Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP ...
emjreviews.com3d
Increased Short-Term Risk of Thyroid Cancer After Starting GLP-1RA Therapy
A recent study has revealed an increased risk of thyroid cancer diagnoses within the first year of starting GLP-1RA therapy.
Healio1d
Top in endocrinology: Notable weight loss with next-gen GLP-1; erectile dysfunction risk
Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...
Monthly Prescribing Reference7d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...